Trial Profile
A Randomized, Open-Label, Single-Dose, Two-Period, Crossover Study to Assess the Bioequivalence of Reference and Test Formulations of Palbociclib Capsule 125 mg Following Oral Administration in Healthy Subjects under Fed Condition
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2018
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Breast cancer; Lung cancer
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Sep 2018 New trial record